What is Ulcerative Colitis (UC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Ulcerative colitis is a chronic inflammatory condition that causes continuous mucosal inflammation of the colon, usually without granulomas on biopsy, and is characterized by a relapsing and remitting course. This definition is based on the most recent and highest quality study available, which provides a comprehensive understanding of the disease 1. The condition typically affects the rectum and to a variable extent the colon in a continuous fashion.

Key Characteristics of Ulcerative Colitis

  • Continuous mucosal inflammation of the colon
  • Usually without granulomas on biopsy
  • Relapsing and remitting course
  • Affects the rectum and to a variable extent the colon in a continuous fashion

According to the latest guidelines and studies, the management of ulcerative colitis involves a patient-centric approach, considering not only the clinical remission but also the quality of life and long-term outcomes of the patients 1. The treatment strategy is mainly based on the severity, distribution, and pattern of the disease, and may include anti-inflammatory medications, corticosteroids, immunomodulators, and biologics.

Treatment Approach

  • Patient-centric approach
  • Consideration of quality of life and long-term outcomes
  • Treatment based on severity, distribution, and pattern of disease
  • Medications may include anti-inflammatory medications, corticosteroids, immunomodulators, and biologics

It is essential to distinguish between mild-to-moderate and severe ulcerative colitis, as the treatment approach and outcomes may vary significantly 1. Mild cases might be managed with mesalamine enemas or oral medications, while severe cases may require hospitalization and intravenous steroids.

Disease Severity and Treatment

  • Mild-to-moderate ulcerative colitis: may be managed with mesalamine enemas or oral medications
  • Severe ulcerative colitis: may require hospitalization and intravenous steroids
  • Importance of distinguishing between disease severity for appropriate treatment approach

In conclusion, ulcerative colitis is a complex condition that requires a comprehensive understanding of its definition, characteristics, and treatment approach to provide the best possible outcomes for patients.

From the Research

Definition and Characteristics of Ulcerative Colitis (UC)

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the gastrointestinal tract, characterized by abdominal pain, chronic diarrhea, rectal bleeding, and weight loss 2, 3, 4.
  • It is one of the two forms of inflammatory bowel disease, affecting 5 million people globally 2.
  • The disease is diagnosed on the basis of clinical parameters and endoscopic-histologic evaluation 5, 4.
  • The cause and etiology of UC remain poorly understood, and there is no cure or 'gold standard diagnostic' for UC 2.

Symptoms and Diagnosis

  • Typical symptoms of UC include bloody diarrhea, abdominal pain, fecal urgency, and tenesmus 4.
  • Extraintestinal manifestations may predate the onset of gastrointestinal symptoms in some patients 4.
  • A diagnosis of UC is made on the basis of presenting symptoms consistent with UC, as well as endoscopic evidence showing continuous and diffuse colonic inflammation that starts in the rectum 4.
  • Biopsies of the colon documenting chronic inflammation confirm the diagnosis of UC 4.

Treatment and Management

  • The approach to therapy of UC has been dependent on the severity of symptoms, with frontline therapy being salicylate-based sulfasalazine 6.
  • Mesalamine, a 5-ASA based agent, is currently available and indicated for the treatment of UC, with response rates between 40%-70% and remission rates of 15%-20% in mild/moderate active disease 6.
  • Other treatment options include oral and rectal 5-aminosalycilates, thiopurines, biological agents targeting tumor necrosis factor and integrins, and small-molecule Janus kinase inhibitors 5, 4.
  • In cases where medical therapy fails or patients develop dysplasia, surgical treatment may be necessary 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ulcerative Colitis.

Mayo Clinic proceedings, 2019

Research

[Management of ulcerative colitis].

Therapeutische Umschau. Revue therapeutique, 2003

Research

The role of mesalamine in the treatment of ulcerative colitis.

Therapeutics and clinical risk management, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.